ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2771

The NKp30/B7H6 Axis Contributes To Pathogenesis In Primary Sjögren’s Syndrome

Gaetane Nocturne1, Sylvie Rusakiewicz2, Damien Sene3, Gunnel Nordmark4, Maija-Leena Eloranta5, Per Eriksson6, Elke Theander7, Helena Forsblad-d'Elia8, Roald Omdal9, Marie Wahren-Herlenius10, Roland Jonsson11, Lars Rönnblom5, Joanne Nititham12, Kimberly E. Taylor13, Christopher J. Lessard14, Kathy L. Moser15, Jacques-Eric Gottenberg16, Lindsey A. Criswell12, Corinne Miceli-Richard17, Laurence Zitvogel18 and Xavier Mariette19, 1INSERM U1012, Université Paris Sud, Le Kremlin Bicêtre, France, 2IGR INSERM U1015, Villejuif, France, 3Internal Medecine, Pitie-Salpetriere Hospital, Paris, France, 4Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, 5Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden, 6Department of Clinical and Experimental Medicine, Rheumatology/AIR, Linköping University, Linköping, Sweden, Linköping, Sweden, 7Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, 8Rheumatology, University of Gothenburg, Gothenburg, Sweden, 9Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, 10Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, 11Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway, 12Department of Medicine, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA, 13University of California, San Francisco, San Francisco, CA, 14Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 15Oklahoma Medical Research Foundation, Oklahoma City, OK, 16Strasbourg University Hospital, Strasbourg, France, 17Rheumatology, Université Paris Sud, Le Kremlin Bicêtre, France, 18IGR INSERM U1015, Villejuif, France, 19Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Sjogren's syndrome and natural killer (NK) cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Sjögren's Syndrome: Basic Science

Session Type: Abstract Submissions (ACR)

Background/Purpose: NK cells are an important subset of cells involved in innate immunity. Their possible role has never been studies in pSS pathogeny. We aimed to assess the involvement of NCR3/NKp30, a NK-specific activating receptor regulating the cross-talk between NK and dendritic cells and type II IFN secretion, and its receptor named B7H6 in pSS pathogenesis.

Methods: First, a cohort of 584 pSS patients (ASSESS + KB cohort) and 451 controls of Caucasian ancestry, addressed by 48 AIMs, was used for exploratory genetic study. Nine single nucleotide polymorphisms (SNPs) within the 6p21.3 NCR3 locus and 3 additional SNP proxies for HLA-DR2,HLA-DR3 and TNF-308 were genotyped. Two NCR3 SNPs (rs11575837, rs2736191) and the SNP proxy for HLA-DR3 (rs2187668) were genotyped in the replication study that included 436 pSS Scandinavian patients and 441 healthy controls. Then, NKp30 mRNA levels were investigated in 102 pSS patients from the French ASSESS cohort according to their genotype. Second, we performed phenotypic characterization of NK cells in 38 pSS patients compared to 30 age-matched controls. The functional relevance of expression levels of NKp30 on NK cells was assessed by a cross-linking assay to analyze degranulation and IFN-γ secretion. Third, we assessed the presence of NK cells by immunohistochemistry (IHC) and transcriptional level of B7H6 within salivary glands. Last we investigated the NKp30-dependent cross-talk between NK cells and epithelial cells within salivary glands.

Results: Our case-control study of genetic polymorphisms of the NCR3/NKp30 gene demonstrated that the rare allele of the rs11575837 (G>A) residing in the promoter was protective for pSS and was associated with reduced gene transcription and function. We also demonstrated that circulating levels of NCR3/NKp30 were markedly increased among pSS patients compared with controls and correlated with higher NCR3/NKp30 IFN-γ secretion by NK cells. Excess accumulation of NK cells in minor salivary glands correlated with the severity of the exocrinopathy. B7-H6, the ligand of NKp30, was expressed by salivary epithelial cells and regulated by TNF-α triggering NKp30 mediated-effector functions.

Conclusion: These findings suggest that NK cells are involved in pSS pathogeny. Different levels of evidence (genetics, mRNA expression, function in blood, presence in the target organ as well as the ligand) demonstrate an NKp30-dependent inflammatory state in salivary glands.  Blockade of the B7H6/NKp30 axis could be clinically relevant in pSS.


Disclosure:

G. Nocturne,
None;

S. Rusakiewicz,
None;

D. Sene,
None;

G. Nordmark,
None;

M. L. Eloranta,
None;

P. Eriksson,
None;

E. Theander,
None;

H. Forsblad-d’Elia,
None;

R. Omdal,
None;

M. Wahren-Herlenius,
None;

R. Jonsson,
None;

L. Rönnblom,
None;

J. Nititham,
None;

K. E. Taylor,
None;

C. J. Lessard,
None;

K. L. Moser,
None;

J. E. Gottenberg,
None;

L. A. Criswell,
None;

C. Miceli-Richard,
None;

L. Zitvogel,
None;

X. Mariette,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-nkp30b7h6-axis-contributes-to-pathogenesis-in-primary-sjogrens-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology